BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination extended mean ...

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...

Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.

Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram ...

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential ...

During the ongoing government shutdown, ClinicalTrials.gov, the nation’s central registry for medical research and clinical ...

The healthcare technology landscape continues to evolve at a remarkable pace, and among the most transformative innovations ...

The Health & Pharma Solutions facility offers state-of-the-art laboratory and training rooms for customersSÃO ...

FutureWise Research, a leading global market intelligence firm, today released a landmark report on Plasmid DNA Manufacturing ...

Introduction: The Power of PurposeWhen people think about careers in science or healthcare, their minds often jump straight ...